Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms

Mei Bao; Mengyu Zhang; Hongxia Shi; Xiaoli Liu; Minghui Duan; Junling Zhuang; Xin Du; Ling Qin; Wuhan Hui; Rong Liang; Meifang Wang; Ye Chen; Dongyun Li; Wei Yang; Gusheng Tang; Weihua Zhang; Xia Kuang; Wei Su; Yanqiu Han; Limei Chen; Jihong Xu; Zhuogang Liu; Jian Huang; Chunting Zhao; Hongyan Tong; Jianda Hu; Chunyan Chen; Xiequn Chen; Zhijian Xiao; Qian Jiang

doi:10.1159/000529750

Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms

Acta Haematol. 2023;146(4):293-306. doi: 10.1159/000529750. Epub 2023 Feb 22.

Authors

Mei Bao¹, Mengyu Zhang¹, Hongxia Shi¹, Xiaoli Liu², Minghui Duan³, Junling Zhuang³, Xin Du⁴, Ling Qin⁵, Wuhan Hui⁶, Rong Liang⁷, Meifang Wang⁸, Ye Chen⁹, Dongyun Li¹⁰, Wei Yang¹¹, Gusheng Tang¹², Weihua Zhang¹³, Xia Kuang¹⁴, Wei Su¹⁵, Yanqiu Han¹⁶, Limei Chen¹⁷, Jihong Xu¹⁸, Zhuogang Liu¹¹, Jian Huang¹⁹, Chunting Zhao²⁰, Hongyan Tong²¹, Jianda Hu²², Chunyan Chen²³, Xiequn Chen²⁴, Zhijian Xiao²⁵, Qian Jiang¹

Affiliations

¹ Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
² Nanfang Hospital, Southern Medical University, Guangzhou, China.
³ Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
⁴ Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
⁵ The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
⁶ Xuanwu Hospital, Capital Medical University, Beijing, China.
⁷ Xi Jing Hospital, The Fourth Military Medical University, Xi An, China.
⁸ Second Hospital of Shanxi Medical University, Taiyuan, China.
⁹ Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
¹⁰ Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
¹¹ Shengjing Hospital Affiliated to China Medical University, Shenyang, China.
¹² Changhai Hospital, Shanghai, China.
¹³ First Hospital of Shanxi Medical University, Taiyuan, China.
¹⁴ Kaifeng Central Hospital, Kaifeng, China.
¹⁵ Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
¹⁶ The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
¹⁷ The First Affiliated Hospital of Xi'an Jiaotong University, Xi An, China.
¹⁸ Qiqihar First Hospital, Qiqihar, China.
¹⁹ The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, China.
²⁰ The Affiliated Hospital of Qingdao University, Qingdao, China.
²¹ The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China.
²² Fujian Medical University Union Hospital, Fuzhou, China.
²³ Shandong University Qilu Hospital, Jinan, China.
²⁴ Institute of Hematology and Affiliated Hospital, Medicine School, Northwestern University, Xi An, China.
²⁵ Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

PMID: 36812897
DOI: 10.1159/000529750

Abstract

Introduction: Genetic landscape, disease characteristics, and clinical outcomes of young adults with myeloproliferative neoplasms (MPNs) were reported. However, data on patient-reported outcomes (PROs) in young adults with MPNs were rare.

Methods: We conducted a multicenter, cross-sectional study to compare the PROs in respondents with thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) by age at survey, including the young group (18-40 years), middle-aged group (41-60 years), and elderly group (>60 years).

Results: Of the 1,664 respondents with MPNs, 349 (21.0%) were young including 244 (69.9%) with ET, 34 (9.7%) with PV, and 71 (20.3%) with MF. In multivariate analyses, the young groups with ET and MF were associated with the lowest MPN-10 scores among the 3 age groups; those with MF, highest proportion of reporting negative impact of disease and therapy on their daily life and work. The young groups with MPNs had the highest physical component summary scores but the lowest mental component summary scores in those with ET. The young groups with MPNs were most concerned about fertility; those with ET, treatment-related adverse events and long-term efficacy of treatment.

Conclusions: We concluded that young adults with MPNs have different PROs compared with middle-aged and elderly patients.

Keywords: MPN-10; Myeloproliferative neoplasms; Patient-reported outcome; Quality of life; Young adults with myeloproliferative neoplasms.

Publication types

Multicenter Study

MeSH terms

Adolescent
Adult
Aged
Cross-Sectional Studies
Humans
Middle Aged
Myeloproliferative Disorders* / diagnosis
Myeloproliferative Disorders* / genetics
Myeloproliferative Disorders* / therapy
Patient Reported Outcome Measures
Polycythemia Vera* / genetics
Primary Myelofibrosis* / diagnosis
Primary Myelofibrosis* / genetics
Primary Myelofibrosis* / therapy
Young Adult